Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on Novo Nordisk's earnings, why the stock is under pressure, and much more.

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

Novo Nordisk's market value fell by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Novo Nordisk faces a significant market value drop amid competition and leadership changes. Maziar Mike Doustdar has been ...

Danish drugmaker Novo Nordisk (NVO) shares tumbled 20% on Tuesday after the company lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and ...

COPENHAGEN (Reuters) -Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss ...

Denmark’s diabetes and obesity giant Novo Nordisk saw its shares plummet more than 27% to 328.20 kroner this morning as it ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...